Search
On March 11, 2026, Shanghai Hemedics Biopharmaceuticals Co., Ltd. made a significant announcement: its independently developed, highly selective small-molecule FGFR2/3 inhibitor, ABSK061, has been awarded the Rare Pediatric Disease Designation by the U.S. Food and Drug Administration (FDA) for the treatment of achondroplasia (ACH). This designation not only acknowledges the clinical significance and research and development potential of ABSK061 but also expedites its global development trajectory. Should this indication receive final approval for market release, Hemedics Pharmaceuticals stands to gain a Priority Review Voucher (PRV). This voucher can be utilized to fast-track the review process for other new drug marketing applications or alternatively, transferred to other entities, thereby conferring substantial strategic and commercial advantages.
-
C114 Communication Network -
Communication Home
